

Press Release  
August 25, 2021

## First US patent granted to Scandion Oncology on combination treatment with its candidate drug SCO-101

**Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that the US Patent and Trademark Office (USPTO) will grant the company's patent US11,103,481 directed to the use of SCO-101, on August 31, 2021.**

The granted patent covers combination therapy with Scandion Oncology's first-in-class lead candidate SCO-101 and is part of the company's patent family originating from the international application PCT/EP2017/061823. The patent claims the use of SCO-101 in combination with different anti-cancer agents across many cancer indications. The Patent Term for the US patent has been extended by 275 days, prolonging the expiry of this patent until January 2038.

"We are pleased that the USPTO has recognized the uniqueness of SCO-101 and granted this patent. This is an important milestone on our journey of developing SCO-101 and internationalizing the company. We have obtained valuable patent protection for SCO-101 in the US, one of our projected key markets, increasing the commercial potential of SCO-101 and creating value for shareholders," said Bo Rode Hansen, President and CEO.

**For further information regarding Scandion Oncology, please contact:**

Bo Rode Hansen, President & CEO  
Phone: +45 3810 2017  
E-mail: [info@scandiononcology.com](mailto:info@scandiononcology.com)  
Website: [www.scandiononcology.com](http://www.scandiononcology.com)

This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 25, 2021, at 8:30 CET

**Scandion Oncology A/S** is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. **Ticker: SCOL.**

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.